A fully Cancer Center-managed facility, the Genomics Technologies Shared Resource consists of the Microarray and Molecular Cytogenetics facilities which provide access to specialized instrumentation and technical expertise in high-throughput genomic technologies and molecular cytogenetics for use in individual and collaborative research programs. Services provided by the facility are: ? Microarray based genome-wide analysis of gene expression, genetic markers, and DNA copy number aberrations ? Microarray based genome-wide analysis of chromatin modifications ? Validation of microarray and other data by high-throughput quantitative PCR ? Molecular cytogenetic analysis by fluorescence in situ hybridization (FISH) and spectral karyotyping (SKY) ? Evaluation and incorporation of emerging genomic technologies and promoting their integration into research programs of HICCC investigators ? Investigator education and advice in adopting genome wide profiling and molecular cytogenetics in their cancer research. The microarray component of the Genomics Technologies Shared Resource thus provides a comprehensive set of integrated genomic analysis tools and services that facilitate the high throughput analysis of genetic and epigenetic alterations in human cancer in basic and translational research programs. These services, which are currently focused on procedures with several different microarray platforms from Affymetrix and Agilent, with ancillary methods including real-time PCR and Phosphorimaging, are closely linked to those provided by the Biomedical Informatics Shared Resource. The molecular cytogenetics facility provides SKY and FISH characterization of human and mouse tumor cells with efficient turnaround times utilizing state-of-the-art technologies. Together these facilities and services provide an integrated platform for basic and translational genomics research in cancer biology at the HICCC. Future plans include evaluating and potentially incorporating an ultra-high-throughput sequencing service into this Resource. During the last period of the CCSG, 53% of the investigators using the facility were Cancer Center members with peer-reviewed funding with those members representing from 50% to 98% of the usage of the available services. The proposed total operating budget of the facility is $392,489, of which we are requesting $ 66,831 from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013696-39
Application #
8375778
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
39
Fiscal Year
2012
Total Cost
$85,007
Indirect Cost
$32,225
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Villasante, A; Sakaguchi, K; Kim, J et al. (2017) Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma. Theranostics 7:4099-4117
Ma, Kevin K; Lin, James; Boudreault, Katherine et al. (2017) PHENOTYPING CHOROIDEREMIA AND ITS CARRIER STATE WITH MULTIMODAL IMAGING TECHNIQUES. Retin Cases Brief Rep 11 Suppl 1:S178-S181
Kampers, Johanna; Orjuela-Grimm, Manuela; Schober, Tilmann et al. (2017) Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leuk Lymphoma 58:633-638
Cabral, Thiago; DiCarlo, James E; Justus, Sally et al. (2017) CRISPR applications in ophthalmologic genome surgery. Curr Opin Ophthalmol 28:252-259
Velez, Gabriel; Bassuk, Alexander G; Colgan, Diana et al. (2017) Therapeutic drug repositioning using personalized proteomics of liquid biopsies. JCI Insight 2:
Dutta, Aditya; Panja, Sukanya; Virk, Renu K et al. (2017) Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5?-reductase Inhibition. Eur Urol 72:499-506
Chiang, Wei-Chieh; Chan, Priscilla; Wissinger, Bernd et al. (2017) Achromatopsia mutations target sequential steps of ATF6 activation. Proc Natl Acad Sci U S A 114:400-405
Marks, Lianna J; Oberg, Jennifer A; Pendrick, Danielle et al. (2017) Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Front Pediatr 5:265
Kanner, Scott A; Morgenstern, Travis; Colecraft, Henry M (2017) Sculpting ion channel functional expression with engineered ubiquitin ligases. Elife 6:
Wang, Tian; Tsang, Stephen H; Chen, Jeannie (2017) Two pathways of rod photoreceptor cell death induced by elevated cGMP. Hum Mol Genet 26:2299-2306

Showing the most recent 10 out of 263 publications